Pulmonary Arterial
 Hypertension (PAH)
 Causes of PAH
 Diet Drugs and PAH
 PAH Symptoms
 & Diagnosis
 Pictures of PAH/PPH
 Medications and Lung  Transplant
   • Endothelin Receptor Antagonists
   • Phosphodiesterase 5 Inhibitors
   • Prostacyclin Medications
 PAH Doctors
 PAH Clinics
 Financial Aid For Patients
 Coping With PAH/PPH
 Ask The Pulmonary
 Hypertension Nurse
                                          
 Search for information:
 
     Match:
any search words
all search words

Click Here for a Free
Information Packet

FOR MORE INFORMATION
Please call
1-800-763-9685

We will gladly answer your questions and send a free packet with additional
information on:

  • New treatment options
  • New clinical trials
  • Doctors
  • Hazardous jobs and products
  • Financial Assistance

 

 



 
Pulmonary Arterial Hypertension

(Primary Pulmonary Hypertension)

           

 

Fen Phen and Primary Arterial Hypertension News

Popular Diet Drugs Pulled From Market
Two of the most popular diet drugs on the U.S. market were recalled Monday after being linked to serious heart damage. The recall was for Redux, known chemically as dexfenfluramine, and Pondimin, also known as fenfluramine. Fenfluramine is half of the popular diet drug combination called fen-phen.

FDA Approves Letairis for Treatment of Pulmonary Arterial Hypertension
The U.S. Food and Drug Administration (FDA) today approved Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension, a rare, life-threatening condition characterized by continuous high blood pressure within the arteries of the lungs.

Ambrisentan Validated by European Medicines Agency
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that GlaxoSmithKline’s Marketing Authorisation Application (MAA) for ambrisentan for the treatment of pulmonary arterial hypertension (PAH) was validated by the European Medicines Agency (EMEA) following a review by the Committee for Medicinal Products for Human Use (CHMP).

Ambrisentan Treatment Appears to Help People With Pulmonary Arterial Hypertension (PAH)
Treatment with the investigative oral agent ambrisentan appear to be helpful for patients with pulmonary arterial hypertension (PAH), researchers reported at CHEST 2006, the annual meeting of the American College of Chest Physicians. Patients were able to achieve the primary endpoint -- increased distance in the 6-minute walk test compared with placebo -- in the Ambrisentan in PAH - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension

Drug Combo May Help Patients Lose Weight
In this study, Wellbutrin, an antidepressant, deals with seratonin. While an antiseizure drug goes for the dopamine, another messenger that tells the brain the body is full

Results of Inhaled Treprostinil PAH Study Reported
This publication details results from an investigator-initiated open-label clinical trial evaluating the effects of inhaled treprostinil as add-on therapy to oral bosentan in the management of pulmonary arterial hypertension.

Four Ambrisentan Studies to Be Presented
Four abstracts describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) and healthy volunteers have been selected for presentation at CHEST 2006

Doctors Treating Patients Using Drug Side Effects
In the unending quest for a miracle diet pill, Americans are trying an array of prescription drugs approved by the Food and Drug Administration to treat a variety of illnesses. None of them have been approved as diet drugs -- but for many, weight loss is a side effect.

Newborn Babies Put At Risk Of PPHN By Antidepressant Use
The antidepressants that increased that risk are in a class called SSRIs or selective serotonin reuptake inhibitors. They include citalopram, fluoxetine, paroxetine and sertraline sold under 19 brand names, including Celexa, Prozac, Paxil and Zoloft.

2,000th Pulmonary Thromboendarterectomy (PTE) Procedure Performed
Chronic thromboembolic pulmonary disease (CTE) rings an ominous death knoll for most people, with blood clots clogging the network of pulmonary arteries that carry blood from the lungs to the heart. But when diagnosed and treated with a pulmonary thromboendarterectomy (PTE), an intricate surgery to remove the clots, many patients can return to a normal life.

New Obesity Treatment Acomplia
Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the United Kingdom, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans.

Family History May Play a Role in Risk for Obesity
A sedentary lifestyle and an unhealthy diet are largely cited as culprits in the ever-increasing numbers of overweight and obese Americans. However, scientists are getting closer to identifying a gene variant that may leave some people more susceptible to obesity.

How Major Weight-loss Drugs Work
Some of the most important weight-loss drugs work by enhancing the effect of the brain chemical serotonin. These include sibutramine (trade name Meridia) and fenfluramine, which was recalled after the combination with dexfenfluramine, called fen-phen, was linked to potentially fatal heart valve abnormalities.

Lorcaserin Drug Produces Significant Weight Loss for Obese
In contrast Redux/Phen-Fen (phentermine and fenfluramine) an earlier anti-obesity drug combination pulled from the market because of cardiovascular complications, was non-selective, and targeted both central and peripheral 5-HT2B receptors. That lack of selectivity likely accounted for the adverse events of valvulopathies and primary pulmonary hypertension seen in some patients who took Phen-Fen

Diet-Drug Case Has Appeals Court Makes Rare Reversal
The reversal by a New York appeals court is but a ripple in the dizzying eddies of litigation in the diet drug drama. The company that made the Fen-Phen combination, Wyeth, has set aside $22 billion for claims, attorneys' fees, and other costs of the legal morass.

Ear Staple Aids In Weight Loss
After the fen-phen scare, Mrs. Elmore began researching natural weight loss alternatives and learned about ear stapling, a method that has been around for about 20 years but has surfaced only recently in the Pittsburgh region.

Hidden Lung Disease May Be Detected Early With Blood Test
A simple blood test may reveal when people with serious respiratory diseases are silently developing high blood pressure in the lungs and predict its effect on survival, a study of 176 patients suggested.

Largest US Lung Transplant Center Has Above Average Survival Rates
The University of Pittsburgh Medical Center (UPMC) is the largest volume lung transplantation center in the United States. In 2005, a record 91 such surgeries were performed, according to new data from the United Network for Organ Sharing (UNOS).

Positive Results for Ambrisentan Trial in Pulmonary Arterial Hypertension
Myogen, Inc. today announced positive top line results of the ARIES-1 trial, the second pivotal Phase 3 trial evaluating ambrisentan, an oral endothelin receptor antagonist (ERA), in pulmonary arterial hypertension (PAH).

Low-Fat Diet is Stupid
On February 8, 2006, the Journal of the American Medical Association delivered a huge blow to advocates of low-fat 'nutrition' by publishing the results of the huge Women's Health Initiative trial. The results of the trial clearly showed that a low-fat diet failed to prevent cardiovascular disease or cancer in women even when followed continuously for eight years.

Ambrisentan ARIES-2 Data to Be Presented
Myogen, Inc. (Nasdaq:MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) has been selected for presentation at ATS 2006

Trial of Ventavis in Combination With Sildenafil for Pulmonary Arterial Hypertension
The clinical trial, called VISION (Ventavis Inhalation with Sildenafil to Improve and Optimize Pulmonary Arterial HypertensioN), is a double-blind, placebo-controlled trial, in which approximately 180 PAH patients treated with a stable dose of oral sildenafil, a PDE-5 inhibitor, will be randomized to one of three treatment groups for 16 weeks: Ventavis four doses per day; Ventavis six doses per day or placebo.

Idiopathic Pulmonary Hypertension Center Gets $1.1 Million
IPAH is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels. In response to these pressure rises, the wall of the pulmonary artery thickens, causing the heart to work harder and eventually fail. What triggers this thickening is not known in a lot of cases. Although there is no known cure for the disease, treatments are available.

Woman Loses Fen-Phen Diet Drug Case Against Wyeth
Wyeth Pharmaceuticals' victory Monday in a fen-phen case tried in a Jefferson County courtroom is bad news for other plaintiffs with cases involving the diet drug, a Beaumont lawyer said.

Initial Lung Function Concerns Don't Stop Exubera Approval
Despite initial concerns regarding lung function, the US Food and Drug Administration (FDA) approved Pfizer's inhaled insulin Exubera for adult patients with type 1 and type 2 diabetes. The approval came on January 27, one day after approval of this drug in the European Union. This inhaled powder form of recombinant human insulin is the first new insulin delivery option introduced since the discovery of insulin in the 1920s.

Other Prescription Weight-Loss Drugs
There are just two weight loss drugs, Xenical and Meridia, that are currently have approval for long-term use in the United States. The FDA is also considering approval of Acomplia

Homecare Urges Congress To Recognize Cost-Effective Role Of Homecare In Medicare, USA
Oxygen can be provided to a chronic obstructive pulmonary disease (COPD) patient who lives at home for one year at less than the average Medicare cost for one day in the hospital, which is $3,606

Antidepressants Pose Persistent Pulmonary Hypertension Risks For Newborns
The antidepressants that increased that risk are in a class called SSRIs or selective serotonin reuptake inhibitors. They include citalopram, fluoxetine, paroxetine and sertraline sold under 19 brand names, including Celexa, Prozac, Paxil and Zoloft.

Positive Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension
Myogen, Inc. today announced positive top line results of the AMB-222 study, an open-label study of ambrisentan in patients with pulmonary arterial hypertension (PAH) who have previously discontinued bosentan and/or sitaxsentan treatment due to liver function abnormalities

Fen Phen Case Settles - Woman Suffered Heart Damage
The lawsuit alleges that Maniscalco suffered heart damage after using the diet drug, which contains an active ingredient called Pondimin and that the drug making, Wyeth, also knew Pondimin was dangerous.

Woman took 1,100 doses of the diet drug Pondimin - loses 'fen-phen' case
A Jasper County jury sided with the manufacturer of the so-called "fen-phen" diet drugs on Monday and denied a Webb City woman with heart-valve disease any damages in her lawsuit against the company.

Advice to Stay Active at Any Size
Very large people face special challenges in trying to be active. You may not be able to bend or move in the same way that other people can. It may be hard to find clothes and equipment for exercising. You may feel self-conscious being physically active around other people.

How Fans Can Achieve VICTORY with Their Health During the Big Game
Oxygen: If you suffer from respiratory conditions such as chronic obstructive pulmonary disease (COPD) or asthma, be sure to have your inhaler available at all times. You may experience excess environmental triggers (such as smoke) at parties, tailgate activities, and during the game that may initiate a respiratory attack.

Orlistat 1st over-the-counter obesity pill to be considered by FDA
The pill, orlistat, would be the only FDA-approved weight loss medication available without a prescription. Orlistat is already sold as a higher-dosage prescription marketed as Xenical.

Lung Health Magazine from American Lung Association
The publication features the latest information on the association's research and programs, advice for managing conditions such as COPD and asthma, answers to questions about lung health, and news about the organization.

The reality of eating disorders
Veronica Portillo took the now banned from the market diet pill Fen-Phen and would use laxatives, throw up and starve herself to keep the weight
off. On a good day she would eat maybe just one small meal. Amaya Brecher gave the audience a dose of reality when she explained the long-term damages her body suffered because of her bulimia. Brecher's esophagus was damaged from the years of purging and it will never heal on its own.

Working Group Report on Competencies for Overweight and
Obesity Identification, Prevention, and Treatment

To advise the NHLBI concerning the structure of a potential Obesity Academic Award, the NHLBI convened a Working Group on May 4-5, 2005 to discuss competencies training for overweight and obesity identification, prevention and treatment. Dr. Robert Kushner, Professor of Medicine, Northwestern University Feinberg School of Medicine, chaired the meeting.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults
The National Heart, Lung, and Blood Institute, in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases, released the first Federal guidelines on the identification, evaluation, and treatment of overweight and obesity.

Clinical Guidelines on Overweight and Obesity in Adults
About 97 million adults in the United States are overweight or obese. Obesity and overweight substantially increase the risk of morbidity from hypertension; dyslipidemia; type 2 diabetes; coronary heart disease; stroke; gallbladder disease; osteoarthritis; sleep apnea and respiratory problems; and endometrial, breast, prostate, and colon cancers.

XOPENEX HFA metered-dose inhaler now available
Reversible obstructive airway disease includes respiratory disorders such as asthma and the reversible component of chronic obstructive pulmonary disease (COPD), affecting approximately 41 million people in the U.S., according to the American Lung Association and Centers for Disease Control and Prevention.

Positive Phase 2b Clinical Trial Results of Novel Anti-Obesity Compound APD356
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from its Phase 2b clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. Over the 12 week treatment period, there was a highly statistically significant (p<0.001) average weight loss of 4.0, 5.7 and 7.9 pounds at daily doses of 10 mg, 15 mg and 20 mg (10 mg dosed twice daily), respectively, in patients taking APD356 compared to 0.7 pounds for the placebo group.

JACC Publication on Tracleer in Children with PAH
Actelion Ltd. announced today that the Journal of the American College of Cardiology (JACC) has published a new study that investigated the long-term outcome of children with pulmonary arterial hypertension (PAH) treated with the dual endothelin receptor antagonist Tracleer(r) (bosentan) with or without concomitant prostanoid therapy.

New Drug Looks Promising For Lung Disease
Dutch doctors are reporting a successful trial of a new drug for chronic obstructive pulmonary disease (COPD), the collective name for lung problems that are the fourth-leading cause of death in the United States.

United Therapeutics Completes European Mutual Recognition for Remodulin(R)
United Therapeutics Corporation announced today that the European Union Mutual Recognition Procedure (MRP) has been completed for Remodulin (treprostinil sodium) Injection for the subcutaneous treatment of NYHA Class III Primary Pulmonary Hypertension patients.

Male sex drug is being used to keep mum Catherine alive
Catherine Lee, of Cottingham, near Hull, is making medical history after being chosen as one of only four women in the world to take Cialis, which is commonly used to treat erection problems in men.

Heart-Lung Transplant Provided Man With Unexpected, Precious Gift Of Time
The former Gaston County track and football star began battling a one-in-a-million disease in 1981. The disease, primary pulmonary hypertension, constricts and damages blood vessels in the lungs, causing the heart to overwork and swell. It has no known cure.

Thomson PPS Launches New Hypertension Web Site
Nearly one in three American adults suffers from high blood pressure (hypertension), according to the American Heart Association. In an effort to help clinicians prevent or minimize their patients' serious health conditions that result from high blood pressure, the National Campaign to Control Hypertension(sm) (NCCH(sm)) is launching its Web site, controlhypertension.org.

Musicians volunteer at Rock Block Party benefit
Martinez is a 17-year-old West Deer native. When he was 15, he passed out while playing paintball with friends and was diagnosed with a congenital lung disease known as primary pulmonary hypertension.

Clinical Trials Currently Enrolling At Rhode Island Hospital For Patients With Pulmonary Arterial Hypertension
Rhode Island Hospital clinical trials for patients with pulmonary arterial hypertension(PPH) includes Ambrisentan in PAH, Flolan to Remodulin Transition Study, Sildenafil, Prostacyclin (Epoprostenol, Flolan, Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil (Cialis), and Iloprost.

Primary or Unexplained Pulmonary Hypertension
Primary or unexplained pulmonary hypertension (PPH) is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.

Predix Pharmaceuticals Initiates Phase I Clinical Trial of 5-HT2B Receptor Antagonist for Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive, debilitating and often fatal disease that results from an increase in pulmonary blood pressure associated with abnormal vascular proliferation.

Community responds when needs appear
Consider the case of Meagan Fowles, the 17-year-old young woman recently diagnosed with primary pulmonary hypertension, and for whom a big fund-raiser was organized.

Ventavis Scrutinized for IPF-Related Pulmonary Hypertension
A medication already approved as a therapy for people with pulmonary hypertension (PH) is about to enter a second round of clinical testing to determine if it's safe for those with PH related to another lung disease known as idiopathic pulmonary fibrosis, or IPF.

Phoenix Area Oxygen Users Enjoy More Active Lives with New Portable O2 System
A self-filling portable oxygen system is dramatically changing the lifestyles of area residents dependent on oxygen, as heavy, cumbersome tanks are replaced by small lightweight canisters that Phoenix area patients can conveniently fill themselves and take anywhere.

Managing Exacerbations of Chronic Obstructive Pulmonary Disease
The worldwide incidence of chronic obstructive pulmonary disease (COPD) is increasing and, in parallel, so is the social and economic burden. Mortality data underestimate COPD as a cause of death because the disease is more likely to be cited as a contributory rather than as an underlying cause of death, or may not be cited at all.

Bill would fund research for Pulmonary Hypertension treatment
The Pulmonary Hypertension Research Act, co-sponsored by Reps. Kevin Brady, R-Texas, and Tom Lantos, D-Calif., may give hope to people like John Kostur, a 42-year-old Maryland resident who suffers from PHT and must wear a device the size of a cassette-tape player that continuously pumps a drug called Flolan into his bloodstream.

Homecare is Cost-Effective for Medicare, COPD, Says Media Survey
Oxygen can be provided to a chronic obstructive pulmonary disease (COPD) patient who lives at home for one year at less than the average Medicare cost for one day in the hospital, which is $3,606 (Annual Statistical Supplement, 2004, Social Security Bulletin).

Changes in Inhaler Devices for Asthma And COPD
Asthma and chronic obstructive pulmonary disease (COPD) involve chronic inflammation and constriction of the bronchioles. Optimal therapy for many patients requires control of both pathologic mechanisms through the use of inhaled bronchodilators and corticosteroids.

Depression Predicts Lung Transplant Quality of Life
While their study focused on patients awaiting transplantation, the researchers say that what they are learning about depression could also help other patients with severe lung disease, such as the estimated 16 million Americans who suffer from chronic obstructive pulmonary disease (COPD).

Allied Healthcare International, Inc. Awarded Contract to Provide Home Oxygen Therapy Service
Currently about 60,000 patients receive home oxygen therapy in England, including those with Chronic Obstructive Pulmonary Disease, lung cancer, heart disease, and cystic fibrosis. Chronic Obstructive Pulmonary Disease alone results in 300,000 emergency hospital admissions every year.

Theravance Announces Initiation of Phase 1 Clinical Study With Investigational Medicine for Respiratory Disease
GSK656398 is an inhaled, long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory disease such as COPD and asthma.

Basket bingo to benefit two Scout leaders with illnesses
As were her family members before her, Peck has been diagnosed with primary pulmonary hypertension - a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.

More Information Released on Thelin Pulmonary Hypertension Drug
The trial, lasting 18 weeks, put the drug Thelin, also known by its generic name sitaxsentan, to the test in a group of 246 patients with the disease.

Man awaits heart and lung transplant surgery
Most people with COPD are smokers or former smokers. Breathing in other kinds of lung irritants, such as pollution, dust, or chemicals, over a long period of time also may cause or contribute to COPD

Novartis's novel bronchodilator paves way for potent COPD combinations
Inhaled beta-2 agonists are commonly used asthma and COPD medications which act as bronchodilators, relaxing and enlarging the airways in the lungs, making breathing easier.

Study: Public Disclosure Makes Docs More Cautious
Do heart doctors who have to publicly report the outcome of every procedure they perform cherry-pick the best patients for surgery, to keep their success rates high?

Aetna Extends Disease Management Program With LifeMasters
LifeMasters offers programs for individuals with diabetes, congestive heart failure (CHF), coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD) and asthma (all of which are fully accredited by the National Committee for Quality Assurance (NCQA)), hypertension, and musculo-skeletal pain.

Therapeutic Inhibition of Matrix Metalloproteinases for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
The incidence of chronic obstructive pulmonary disease (COPD) is increasing worldwide and is ranked as the fourth most common cause of death in the United States. COPD is caused by long-term exposure to cigarette smoke, toxic gases, and particulate matter, leading to airway flow limitation and pulmonary failure.

A Phase III, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment with an Open-label Bosentan Arm in Patients with Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to evaluate the safety and efficacy of Thelin™ as compared to placebo in the treatment of patients with PAH. A cohort of patients will be randomized to usual treatment with bosentan for observational comparisons of safety and efficacy.

Sitaxsentan Results in Pulmonary Arterial Hypertension Published in The American Journal of Respiratory and Critical Care Medicine
The reported study is based on Encysive's Phase IIb/III STRIDE-1 (Sitaxsentan To Relieve ImpaireD Exercise) clinical study in Pulmonary Arterial Hypertension (PAH).

TOPIGEN Introduces FANA(TM) Technology, New 3rd Generation Chemistry for Oligonucleotide-Based Therapeutics
TOPIGEN Pharmaceuticals Inc., a developer of multi-targeted respiratory products that inhibit pathways involved in cellular recruitment and inflammation, today introduced FANA(TM) Technology, a new generation of chemistry with potential for broad gene-targeting drug applications.

Dissociation of Lung Function and Airway Inflammation in Chronic Obstructive Pulmonary Disease
Relationships between airway inflammation and lung function in COPD do exist, but they are not simple and easily detectable, because even the exacerbations are associated with a lower and more variable inflammatory response than those in patients with asthma

Shirley woman with Primary Pulmonary Hypertension disorder credits miracles
As one of the country's longest-living survivors of primary pulmonary hypertension, a blood vessel disorder of the lungs, Morrill relies on the tiny pump and tube that snakes from the bag into her heart to deliver medicine from the cassette every 35-40 seconds.

Cholesterol Therapy Could be Beneficial For Pulmonary Hypertension Patients
Primary PH is diagnosed in people without a known cause. It is extremely rare, occurring in approximately 2 people for every million each year. Secondary PH, on the other hand, can be caused by any number of factors, including the breathing disorders emphysema and bronchitis (known collectively as chronic obstructive pulmonary disease (COPD)); or inflammatory or collagen vascular diseases like scleroderma, CREST syndrome, or systemic lupus erythematosus (SLE).

Acetaminophen May Boost Risk of COPD, Study Suggests
A heightened use of the pain-reducing drug, acetaminophen, may increase the risk of developing asthma or chronic obstructive pulmonary disease (COPD), according to a study from a group of international researchers

FDA Clears Way for New PH Drug Sildenafil Citrate
People with pulmonary hypertension now have a new treatment option at their disposal. The U.S. Food and Drug Administration has approved the drug Revatio, known by its generic name sildenafil citrate, for pulmonary arterial hypertension, says its manufacturer, Pfizer.

UPDATE: Docs Release More Findings in Thelin PH Drug Trial
The trial, lasting 18 weeks, put the drug Thelin, also known by its generic name sitaxsentan, to the test in a group of 246 patients with the disease. A group in the study also received the already approved PH drug, Tracleer (bosentan), to compare the results.

Medford kids join Miles for Miracles walk
O'Donnell was diagnosed at age 6 with primary pulmonary hypertension, a rare condition in which the blood vessels in the lungs have a much higher pressure than normal, causing shortness of breath and the inability to do normal activities.

New GSK Chair in Airway Inflammation Established at University of Alberta
Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) significantly impact the quality of life for many Canadians, and funding for clinical and basic research in this area is critical

Key Homecare Messages for Congress Readied for Washington Conference Next Week
Home inhalation drug therapy provides critical care to nearly one million Medicare beneficiaries suffering from chronic obstructive pulmonary disease and other respiratory illnesses.

Heart boy waits for lifesaving double transplant
A boy aged five who suffers from an incurable illness has been put on an urgent waiting list for a double heart and lung transplant in a last-ditch attempt to save his life.

Wyeth Says Jury Awards Diet-Drug Users $200 Million (Update2)
A Pennsylvania jury decided that two former users of Wyeth's drugs taken as part of the fen-phen diet combination deserved $200 million in damages for heart problems caused by the medicine.

NI leads respiratory disease battle
Respiratory disease, including asthma, accounts for almost 15% of all deaths in Northern Ireland and is a significant cause of disability in society, said the Department of Health.

Florida Acts To End Payment Of Erectile Drugs For Ex-Cons
In Florida's case, that meant the end to reimbursement for every Medicaid recipient's erectile dysfunction prescription, with the exception of patients who use Viagra to treat primary pulmonary hypertension, a potentially life-threatening condition.

Female lung transplant recipients at greater risk of acute lung injury
According to the United Network for Organ Sharing (UNOS) there are currently 3,688 Americans waiting for a lung transplant for diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), primary pulmonary hypertension and pulmonary fibrosis.

Ambrisentan PAH Long-Term Safety and Efficacy Data Presented at ATS 2005 San Diego
The one-year data demonstrate that ambrisentan produced a significant and durable benefit on exercise capacity and other clinical measures of PAH.

Researchers Present Data That Support Inhaled Iloprost Therapy in Patients With Pulmonary Arterial Hypertension
CoTherix, Inc. (Nasdaq: CTRX - News) announced today that researchers have presented results involving inhaled iloprost therapy for the treatment of pulmonary arterial hypertension (PAH), a debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries.

PR Pharmaceuticals’ PulmoLAR(TM) Granted Orphan Drug Status
PR Pharmaceuticals Inc. (PRP), announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead compound, 2-methoxyestradiol (2ME or PulmoLAR(TM)), for the treatment of pulmonary arterial hypertension (PAH).

New Ventavis(R) Data to Be Presented at American Thoracic Society's International Conference
Ventavis® is marketed in the United States by CoTherix for the treatment of pulmonary arterial hypertension, a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs, in patients with NYHA Class III or IV symptoms

Myogen Initiates Trial of Ambrisentan in Patients Who Previously Failed Other ERA Therapy
Ambrisentan is an ETA selective endothelin receptor antagonist being developed as an oral therapy for patients with PAH. Ambrisentan has been granted orphan drug designation for the treatment of PAH in both the United States and European Union.

Medical Researchers Say Statins, Other
Cholesterol-Depleting Agents Affect Hypertension
Patel said the team found a previously unappreciated cellular and molecular mechanism for the disease process in idiopathic pulmonary hypertension (IPAH), which was previously called primary pulmonary hypertension.

Judge rescinds $1.4 million fen-phen verdict
The Madison, New Jersey-based company said Judge Mark Bernstein of the Philadelphia Court of Common Pleas ruled that the sole expert witness for the women had systematically provided questionable or "illogical" scientific testimony.

Fat Chances
Arena's pill was born from one of the drug industry's biggest disasters: the diet combo fen-phen. That combo of two medicines, fenfluramine and phentermine, damaged the heart valves of some of the people who took it. Fenfluramine was withdrawn from the market, resulting in massive legal costs for drugmaker Wyeth

Barrington native needs double lung transplant
In September of 2003, Ms. Foley was five months pregnant and visited her doctor after experiencing shortness of breath. What followed was immediate hospitalization and an unexpected diagnosis: primary pulmonary hypertension.

2 Fen-Phen defendants must serve prison time
Durrell and Johnson are among the 12 Fayette defendants charged last year in a joint FBI/IRS investigation in connection with the settlement from American Home Products, the maker of the diet drug.

Family trees may lead to better hypertension care
High blood pressure, or hypertension, is a condition that can lead to a heart attack or stroke, which together are the country's No. 1 killer. It affects about five million adult Canadians.

Save Siti give her life
Called primary pulmonary hypertension, her condition is considered a genetic disorder and it could lead to heart failure and eventually death.

More guilty pleas in Fen-Phen case
A person who recruited Fen-Phen clients on behalf of a Jackson law firm is cooperating with an ongoing federal investigation that has resulted in convictions of a dozen people who falsely said they were harmed by the diet drug.

Predix Pharmaceuticals Initiates Phase I Clinical Trial of 5-HT2B Receptor Antagonist for Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive, debilitating and often fatal disease that results from an increase in pulmonary blood pressure associated with abnormal vascular proliferation.

Myogen Reports 2005 First Quarter Results
The company has three product candidates in late-stage clinical development: enoximone capsules for the treatment of patients with advanced chronic heart failure, ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant systolic hypertension.

Benefit helps to keep spirits high for Auburn woman
Wells was diagnosed with primary pulmonary hypertension, a rare blood vessel disorder of the lungs in which the pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) rises above normal levels.

Fen-Phen Plaintiff Who Lost Jury Trial Wants Judgment
The jurors unanimously concluded the diet drug Pondimin had injured Vega's aortic heart valve, awarding her $5 million in potential damages.

Hampton residents rallies around sick teenager
An athletic and extroverted teen, Justin was diagnosed two years ago with primary pulmonary hypertension, a condition that will require either a double lung transplant or a heart and lung transplant, his doctors say.

Cough may not have pulmonary source
Chronic cough may not always indicate a primary lung disorder, such as pneumonia or bronchitis. Postnasal drip (sinus drainage from allergies), chronic sinus infection, heart failure and hiatal hernia are associated with a troublesome, dry cough. Also, certain drugs (notably the ACE inhibitors used for heart disease and hypertension) will cause a chronic, racking cough in about 10 percent of users.

FDA Sends Warning Letter to United Therapeutics Corp. Over Remodulin Advertisement
The booklet asks the question, “How is Remodulin Therapy different from Flolan Therapy?” It then highlights the putative advantage of Remodulin: that it is given subcutaneously, as opposed to the central infusion needed for Flolan.

Federal Judge Dismisses Fen-Phen-Related Action Against Napoli Law Firm
A settlement was eventually reached with American Home Products that was believed to be worth hundreds of millions of dollars and, the plaintiffs alleged, called for Napoli Kaiser to receive a contingency fee of one-third the total amount.

Fen-phen foundation pays four $60,000
In a new lawsuit, more than 300 of the plaintiffs say that it is inappropriate for the legal team to be paid again after they received tens of millions of dollars in legal fees.

Cholesterol Therapy Could be Beneficial For PH Patients
The drugs, including those known as statins, may modify cellular calcium that contributes to the development of pulmonary hypertension.

Can 2 Garlic Cloves a Day Keep the Doc Away?
In primary pulmonary hypertension, blood has a hard time leaving the right side of the heart. The culprit: tight blood vessels in the lungs. Symptoms include: shortness of breath, especially during exercise; chest pain; and fainting episodes. The exact cause of primary pulmonary hypertension is unknown.

13 years after successful transplant, family waits again
At age 34, she was diagnosed with primary pulmonary hypertension, where the blood vessels in her lungs constricted, keeping the blood from going through to her heart.

Ingredient in garlic protects against severe chronic pulmonary hypertension in rats
The human form of the disease primary pulmonary hypertension often leads to cardiovascular complications such as right heart hypertrophy and failure and is frequently lethal.

Statins, other cholesterol depletors, may disrupt hypertension development: UCSD study
Cholesterol-lowering agents, such as the widely-prescribed statin drugs, and cholesterol-blocking agents may prove to be "novel therapeutic agents to modify cellular calcium that contributes to the development of pulmonary hypertension"

Potential Damages of $5 Million Awarded in Fen-Phen Suit
A Philadelphia jury awarded $5 million in potential damages Wednesday to a Utah woman who claimed the diet-drug compound fen-phen damaged her aortic heart valve.

THE TRANSPLANT ODYSSEYS UPHILL, DOWNHILL
She'd gotten sick at the age of 19 and was eventually diagnosed with primary pulmonary hypertension and Osler-Weber-Rendu syndrome, a genetic disorder.

Tragic girl's words live on to inspire...
Victoria had been dogged by health problems from an early age. She was born with a heart murmur, without a spleen and had gut and liver problems so serious that a simple cold could have put her life in danger.

Frost & Sullivan Recognizes InterCure for Hypertension Treatment Technology Innovation
With multiple published clinical trials and thousands of advocates, both patients and physicians, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. Besides being the only therapeutic self-care device treating a major cardiovascular condition, RESPeRATE(R) has become the first hypertension treatment available over-the-counter (OTC).

Primary or Unexplained Pulmonary Hypertension
Primary or unexplained pulmonary hypertension (PPH) is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.

United Therapeutics Announces Approval of Remodulin(R) in France
United Therapeutics Corporation (Nasdaq: UTHR) announced today that AFSSAPS, the French drug regulatory agency, has issued an approval letter for Remodulin (treprostinil sodium) Injection for subcutaneous treatment of NYHA Class III Primary Pulmonary Hypertension patients.

Lung criteria changes will happen soon
The United Network for Organ Sharing and the Organ Procurement and Transplantation Network revised the U.S. lung allocation policy in June. Implementation of the new criteria is anticipated this spring.

Diet pills can be deadly
Fenfluramine intake has been associated with an increase in the number of people who develop a disease called Primary Pulmonary Hypertension (PPH), which is fatal in most cases.

ALM's The American Lawyer Examines Fen-Phen Settlement
After reports that the popular diet drug fen-phen caused damage to heart valves, American Home Products, now Wyeth, pulled its two fen-phen products off the market in 1998.

There are ways to modify your risks for heart disease, our leading killer
Modifiable risk factors, such as hypertension, elevated lipid levels, smoking, inactivity, stress and excess weight can be managed if one is motivated to change. Perhaps one of the most powerful motivators for making a lifestyle change is having experienced unstable angina, a heart attack or open heart surgery.

When Law Firms Collide, Things Sometimes Get Ugly
Parker & Waichman referred cases to Napoli Bern (and maybe also worked on them - that is one of the many issues in dispute) involving people who had taken the diet drug combination fen-phen, which could cause heart valve damage. According to court documents, Napoli Bern, in turn, helped negotiate a settlement with fen-phen's maker, Wyeth.

The Critically Ill Patient With Pulmonary Hypertension
Pulmonary hypertension (PH) is a common problem in the intensive care unit (ICU). PH can arise in critically ill patients as a consequence of acute respiratory distress syndrome, as a result of the mode of mechanical ventilation (MV) used, or as complication of the patient's underlying disease (eg, emphysema). Additionally, there is growing appreciation of the significance of primary pulmonary hypertension (PPH) in the ICU.

Fen-Phen Case Lawyers Say They'll Reject Wyeth Offer
Lawyers for thousands of people who contend that they were harmed by the diet drug combination fen-phen said yesterday that they would reject a comprehensive settlement offer from Wyeth whose products, Redux and Pondimin, made up half the combination fen-phen. The two drugs were withdrawn in 1997 after disclosures that they caused serious heart valve and lung damage in some patients.

Long-Term Survival Using Tracleer for PPH Faces Scrutiny
A new, oral medication Tracleer approved as a therapy for primary pulmonary hypertension (PPH) was tested recently in a large study, and the physicians who participated concluded the Tracleer drug improved survival for PPH patients as compared to the odds with no treatment.

Ambrisentan PAH Long-Term Safety and Efficacy Data to Be Presented at ATS 2005 - San Diego
The one-year data demonstrate that ambrisentan produced a significant and durable benefit on exercise capacity and other clinical measures of PAH.

Science takes uneasy role in product liability cases
When word spread that people injured by the fen-phen diet drug cocktail could share in a multibillion dollar legal settlement, law firms began sponsoring health screenings so large that a judge quipped that one doctor's work "would have been the envy of Henry Ford."

Scientific Publication on Long-Term Bosentan Use in PPH
Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today the publication of the scientific paper evaluating disease outcome of patients with advanced primary pulmonary arterial hypertension receiving Tracleer(r) (bosentan).

Fitch Affirms Wyeth's 'A-/F2' Senior Unsecured & CP Ratings
The fourth-quarter diet drug charge is a 'best estimate' of all remaining litigation exposure from initial and downstream opt-outs, primary pulmonary hypertension (PPH) cases, and Seventh Amendment claimants. Previous diet drug charges were determined using 'minimum reasonably estimatable' accounting.

Wyeth Reports Results for the 2004 Fourth Quarter and Full Year
The balance in the reserve represents management's best estimate of the aggregate amount required to cover diet drug litigation costs, including payments in connection with the National Settlement (as it would be amended by the proposed Seventh Amendment), initial opt outs, PPH claims, downstream opt out cases, and the Company's legal fees related to the diet drug litigation.

Fen-phen settlement is back in the courtroom
The Ashland man joined a class-action lawsuit against fen-phen manufacturer American Home Products in 1998. The case was eventually settled in 2001 and Parker received two separate settlement checks for undisclosed amounts.

Herpesvirus and pulmonary hypertension
Primary pulmonary hypertension is characterized in part by vascular lesions in the lung, and may lead to heart failure. Some cases are associated with genetic susceptibility, the investigators noted, but the pathogenesis of most cases is not known.

Transplanted lungs breathe life into Hampden woman
The cause of primary pulmonary hypertension is not known, though the illness can run in families and is most common in women of Amy's age, said Jenny Foertch, Amy's lung transplant coordinator at the Cleveland Clinic, a nationally known organ transplant center.

Losing is everything
I tried a thing called AYDS gum. That was for your appetite. I tried Metabolife. I did fen-phen. Mixed berry fruit drink. I did Medifast and NutriMed. Seven hundred calories a day. And that was besides any diet I found in Family Circle or Woman's Day.

Fen Phen Nation
In the 1990s, America's desire to be thin led to a craze for diet drugs -- including the infamous Fen Phen "cocktail." A brief look at the background of the Fen Phen fiasco and its impact.

Weight's almost over: obesity research developments
While obesity is now recognized as a disease in its own right, it is also one of the key risk factors for other chronic diseases. Non-fatal, health problems include respiratory difficulties, chronic musculoskeletal problems, skin problems and infertility.

Public 'Defenseless' Vs. Bad Drugs
Graham told the committee that research indicated that Vioxx caused up to 160,000 heart attacks and strokes. He said his research helped persuade the FDA to withdraw a number of drugs, including Fen-phen, a weight loss drug.

Diet Doctor Robert Beale Jr. Dies
Nonetheless, Dr. Beale's medical license was not suspended, and when the diet drug combination "fen-phen" -- later linked with several deaths -- was introduced in the 1990s, he refused to prescribe it.

3 Fen-Phen victims win $500,000
This was the 10th fen-phen case to be tried in the same Philadelphia court since July. Wyeth has set aside more than $16 billion to resolve cases involving the Fen-Phen mixture, which included the company's Pondimin or Redux and generic phentermine.

Come along on a ride to some unchecked virtual drugstores
Phentermine, which regulates sleep, body temperature and appetite, according to Ohio Northern University pharmacy professor Karen Kier, was a component of "Fen-phen," the popular diet drug withdrawn from the market in 1997 because of links to heart- valve disease.

Ex-owner of pharmacy to speak in D.C.
In Mississippi, Bankston has been a poster child for those pushing tort reform, an example of a small business being sued repeatedly in drug litigation for filling a doctor's prescription.

Families reflect on ultimate gift - An organ donation is a bequest that keeps giving
When Jean Swartling, of Sun Valley, took on a hiking trip to Italy in 1996 she went without realizing she was already suffering from Primary Pulmonary Hypertension, a disease which constricts the blood vessels going to the lungs thus depriving them of oxygen.

Imaging Technique Helps Researchers Probe Lung Vessel Changes
PPH has been linked to using diet drugs or anorectic compounds such as Phen-Fen. In PPH the pulmonary hypertension is itself the underlying health problem.

NY Firms Sue Each Other Over Fen-Phen Fees
A New York judge has ruled that a plaintiff's law firm that referred clients to another firm can sue the latter firm for allegedly shortchanging referred clients in a global settlement of "fen-phen" diet drug lawsuits.

One doctor's long trail of dangerous mistakes
At the VA medical center, former co-workers remember him in rumpled khakis, singing along with Elvis recordings during autopsies or lamenting the ban on the diet drug combination fen-phen.

How to Improve Drug Safety
In the high-profile case of fen-phen, the diet drug combination that damaged the heart valves of thousands of consumers, the FDA had never approved the drug therapy for long-term weight loss.

PPH News Archives - Current month's news
JanuaryFebruaryMarchAprilMayJune
JulyAugustSeptemberOctoberNovemberDecember

Predix Pharmaceuticals Initiates Phase I Clinical Trial of 5-HT2B Receptor Antagonist for Pulmonary Hypertension
As a selective 5-HT2B antagonist, PRX-008066 has the potential to act both as a vasodilator of pulmonary but not systemic blood vessels, and as a disease-modifying agent to slow the progression of the disease.

Enrollment Completed in Phase 2b Trial of Darusentan in Patients With Resistant Systolic Hypertension
Hypertension affects approximately 50 million individuals in the United States and approximately one billion worldwide. Despite the availability and use of several classes of drugs (diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, central alpha receptor agonists, peripheral antagonists and vasodilators) to treat hypertension

New Thelin Data to be Presented at American Thoracic Society's International Conference
Pulmonary arterial hypertension (PAH) is a condition that involves high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs.

Medtronic Announces Expanded Labeling for Its Model 407C General Medication Pump
The external pump can deliver medications to treat a variety of medical conditions including, but not limited to, cancer and pain. Currently, Medtronic's general medication pump is being used to deliver Remodulin(R), manufactured by United Therapeutics Corporation (NASDAQ:UTHR), for the treatment of pulmonary arterial hypertension.

International Approvals: Follistim, Tracleer, Prograf
On April 11, the Japanese Ministry of Health, Labor, and Welfare approved bosentan tablets (Tracleer, made by Actelion, Ltd) for the treatment of all forms of pulmonary arterial hypertension (PAH) in patients with World Health Organization class III or IV symptoms to improve exercise ability and decrease the rate of clinical worsening.

Actelion Ltd: Japanese Approval for Tracleer in PAH
Actelion Ltd announced today that the Japanese Ministry of Health, Labor and Welfare has granted formal approval for Tracleer (bosentan) in Pulmonary Arterial Hypertension (PAH). Tracleer has been approved for patients suffering from all forms of PAH

International Approvals: Ceplene, Reducol, Remodulin
French regulatory authority (Agence Française de Sécurité Sanitaire des Produits de Santé) approved treprostinil sodium injection (Remodulin, made by United Therapeutics Corp.) for subcutaneous administration in the treatment of primary pulmonary arterial hypertension (PAH)

A Drug to Get Your Blood Pumping
One approved drug is Tracleer, from Swiss company Actelion. Tracleer has been commercially successful, with sales of several hundred million dollars a year.

Encysive Drug Study Comes To An End
A 50 mg dose of Thelin improved 6MW by 24.2 meters, and bosentan (Tracleer), currently the only approved oral agent for treating PAH, improved 6MW by 29.5 meters.

Wait is over: Woman gets heart, lungs
Vulhop had a complex congenital heart defect known as double outlet right ventricle, and developed severe pulmonary hypertension and congestive heart failure.

New PH Therapy Gets FDA Nod
Current therapy includes a range of medications to alleviate constricted pulmonary vessels like calcium channel blockers, epoprostenol (Flolan), Remodulin (treprostinil), and warfarin (Coumadin).

Taking liver-taxing drugs calls for periodic testing
Following is a representative list of drugs that call for liver function monitoring to help ensure safe use: Acarbose (Precose), amiodarone (Cordarone), amprenavir (Agenerase), atorvastatin (Lipitor), azathioprine (Imuran), bosentan (Tracleer), carbamazepine (Tegretol), celecoxib (Celebrex)...

CoTherix's Ventavis(R) Commercially Available for the Treatment of Pulmonary Arterial Hypertension
Based on the positive results from our STEP trial evaluating the combination of Ventavis added to Tracleer therapy, we believe there is an opportunity for Ventavis to be used early in the course of the disease

Renin Alliance of Actelion and Merck & Co., Inc. Achieves Second Milestone
Actelion and Merck formed an exclusive worldwide alliance in December 2003 to discover, develop and market new classes of renin inhibitors for patients suffering from cardio-renal diseases.

CoTherix Reports Positive Clinical Data From STEP Study
The analysis of this study showed that the combination of Ventavis® (iloprost) Inhalation Solution added to Tracleer® (bosentan) therapy was well tolerated and provided clinical benefit in patients with pulmonary arterial hypertension (PAH).

Speedel Brings In CHF47.8M To Advance Pipeline Projects
SPP200, a recombinant human protein undergoing a Phase II trial for an undisclosed cardiovascular indication, remains under Speedel's control, but an undisclosed U.S. pharmaceutical firm, which originally discovered the compound, retains a callback option.

Long-Term Survival Using Tracleer for PH Faces Scrutiny
A new, oral medication approved as a therapy for primary pulmonary hypertension (PH) was tested recently in a large study, and the physicians who participated concluded the drug improved survival for patients as compared to the odds they might have faced with no treatment

Actelion Provides Update on Bosentan in Japan
Tracleer(r), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion subsidiaries in the United States, the European Union, Australia, Canada, Switzerland, Israel, Hong Kong, Malaysia, Singapore and Brazil as well as several other smaller territories worldwide.

The Critically Ill Patient With Pulmonary Hypertension
Pulmonary hypertension (PH) is a common problem in the intensive care unit (ICU). PH can arise in critically ill patients as a consequence of acute respiratory distress syndrome, as a result of the mode of mechanical ventilation (MV) used, or as complication of the patient's underlying disease (eg, emphysema).

Encysive Drug Thelin Meets Study Endpoint
Compared with Actelion's Tracleer, currently the only approved oral treatment for pulmonary arterial hypertension, a 50 mg dose of Thelin improved the walk by 24.2 meters, and Tracleer improved the walk by 29.5 meters.

FDA Safety Labeling Changes: Depo-Provera, Tracleer, Tabloid
FDA approved revisions to the safety labeling for bosentan (Tracleer tablets, made by Actelion, Inc.), warning that concurrent use of transdermal hormonal contraceptives (in addition to oral, injectable, and implantable formulations) may decrease the contraceptives' efficacy and that they should not be relied on as a sole means of contraception.

Actelion Ltd -- Scientific Publication on Long-Term Bosentan Use in PPH
A total of 245 patients with PAH were enrolled in the two placebo-controlled trials. At the end of these studies, all patients were offered bosentan therapy. The results published today are from the long-term follow-up of the 169 patients with primary pulmonary hypertension (PPH).

Long-term treatment with bosentan improves outcomes in pulmonary arterial hypertension, European Respiratory Journal
Bosentan, a dual endothelin receptor antagonist, is the first approved oral treatment for PAH. In short-term (12-16 week) trials, bosentan has demonstrated improvements in how far patients can walk and how they feel.

Long-Term Survival Using Tracleer for PPH Faces Scrutiny
A new, oral medication Tracleer approved as a therapy for primary pulmonary hypertension (PPH) was tested recently in a large study, and the physicians who participated concluded the Tracleer drug improved survival for PPH patients as compared to the odds with no treatment.

Scientific Publication on Long-Term Bosentan Use in PPH
Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today the publication of the scientific paper evaluating disease outcome of patients with advanced primary pulmonary arterial hypertension receiving Tracleer(r) (bosentan).

3 Fen-Phen victims win $500,000
This was the 10th fen-phen case to be tried in the same Philadelphia court since July. Wyeth has set aside more than $16 billion to resolve cases involving the Fen-Phen mixture, which included the company's Pondimin or Redux and generic phentermine.

Public 'Defenseless' Vs. Bad Drugs
Graham told the committee that research indicated that Vioxx caused up to 160,000 heart attacks and strokes. He said his research helped persuade the FDA to withdraw a number of drugs, including Fen-phen, a weight loss drug.

Acomplia diet drug shows real promise
In early clinical trials, Acomplia is looking promising. But with only 3,000+ people tested so far, it's far from being approved by the FDA. And even as effective as Acomplia appears to be in early tests, much of the hype is overblown

Wyeth Backs Changes to Diet Drug Settlement
Wyeth said it is endorsing the proposed changes after their approval by an overwhelming majority of former users of its two drugs, Pondimin and Redux. The drugs were recalled in 1997 after being linked to heart valve damage and a highly fatal lung condition.

FDA Approves Breakthrough Therapies
The FDA in 2004 approved 32 new therapeutic products discovered, developed or marketed by biotechnology and related companies, according to a BIO analysis

FDA Approves Ventavis(TM) for the Treatment of Pulmonary Arterial Hypertension (PAH)
CoTherix, Inc. today announced that following priority review, the U.S. Food and Drug Administration (FDA) has approved Ventavis(TM) (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms

FDA Approvals: Ventavis, Kepivance, Captique
The U.S. Food and Drug Administration (FDA) has approved iloprost inhalation solution for the treatment of severe pulmonary arterial hypertension

Viagra helps boy with lung disease
"They told us we could try him on either Flolan, which is an IV drug. He would have to wear a pack continuously... Or they could try a new drug, which was the Viagra," said Jennifer Gendron.

New Treatment, Significant Improvement for HIV-related Heart Condition
Treatment with the oral drug bosentan (Tracleer) led to significant improvements in an often fatal disease, pulmonary arterial hypertension, according to a new study. PAH is usually linked with human immunodeficiency virus infection.

Patients call for an end to red tape
About 30 patients who suffer from a rare lung disease known as pulmonary arterial hypertension (PAH) yesterday called on the government to relax regulations on life-saving drugs and give them the costly medication before the disease catches up with them.

Actelion Initiates Phase IIb/III Program With Clazosentan
Actelion Ltd announced today it has initiated the comprehensive global Phase IIb/III development program for clazosentan, an intravenous endothelin receptor antagonist.

Scientific Publication of RAPIDS-1 Study with Bosentan
Tracleer(r), the first orally available dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic life-threatening condition that severely compromises the function of the lungs and heart is already approved in the US

CoTherix Gets Approval For Inhaled PAH Drug Ventavis
Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003.

TRACLEER WILL NOT EXPAND INTO TREATMENT OF CONGESTIVE HEART FAILURE
In late November, the FDA approved Tracleer for the treatment of PAH. The drug is indicated to improve exercise ability and decrease the rate of clinical worsening in PAH patients with significant limitation of physical activity. Tracleer is the first approved oral treatment for PAH patients.

Lung disease drug Tracleer 'a revolution'
Tracleer today became the first drug listed on the Pharmaceutical Benefits Scheme to help control the lung disease pulmonary arterial hypertension (PAH). The disease mostly affects women aged 20 to 45, but also occurs in young children and adult men.

Successful study with Tracleer® (bosentan) in scleroderma patients
Tracleer®, the first orally available dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic life-threatening condition that severely compromises the function of the lungs and heart is already approved in the US

New scientific studies show higher than expected prevalence of Pulmonary Arterial Hypertension in patients with Connective Tissue Diseases (CTD)
Two scientific studies at the American College of Rheumatology report a high prevalence of diagnosed and undiagnosed pulmonary arterial hypertension (PAH) in patients with scleroderma and mixed connective tissue disease (MCTD)

Bosentan in metastatic melanoma well tolerated at high doses
All these trials involving the orally available dual endothelin antagonist bosentan (Tracleer®), currently approved for the treatment of Pulmonary Arterial Hypertension (PAH), are now recruiting as scheduled.

Actelion reports further progress to additional markets for Tracleer in Pulmonary Arterial Hypertension
Around 100,000 people in Europe and the US currently suffer from pulmonary arterial hypertension, which includes PPH or PAH related to other diseases such as scleroderma, a degenerative connective tissue disease.

Results of Treatment with Oral Tracleer (bosentan)
Actelion Ltd (SWX: ATLN) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA) Tracleer® (bosentan) in the treatment of pulmonary arterial hypertension (PAH) related to HIV (human immunodeficiency virus) infection.

Analysis suggests Tracleer® (bosentan) improved survival in primary arterial hypertension patients
Actelion announced the analysis of long-term follow-up data of primary pulmonary hypertension patients from Tracleer® pivotal registration studies that suggests the oral dual endothelin receptor antagonist is associated with improved survival.

FREE
PAH/PPH Patient
Info Packet
PPH Patient Handouts
Click here today,
and get this free patient information packet sent to you quickly.



 Popular Searches  
fen phen
pah symptoms
heart attack
hypertension

 


To Obtain the Best Treatment Info & Financial Assistance contact us for a free PAH/PPH information packet which includes:

Hospital Locations
Clinical Trials
Hazardous Jobs/ Products
New Treatment Options
Doctors
Financial Assistance

Fill out the form below or call 1-800-763-9685.

First Name
Last Name
Address
City
State
Zip

Phone

Email
   
Have you or a loved one been diagnosed or have:
   
Pulmonary Hypertension?

  Yes   No
Primary Pulmonary Hypertension
(PPH)?
  Yes   No
Pulmonary Arterial Hypertension
(PAH)?
  Yes   No

Persistent Pulmonary Hypertension Newborn?

  Yes   No
Have you had a Valve Replacement?

  Yes   No
Are you on a treatment such as Flolan, Tracleer, Remodulin, Rivatio (Viagra), Ventavis, or other?

  Yes   No
Did you or your loved one take Fen Phen or other Diet Drugs?

  Yes   No
Did Mom take any antidepressant while pregnant resulting in a child with a diagnosis of Persistent Pulmonary Hypertension Newborn?
  Yes   No
   

Comment /
Info Request

Privacy Policy

 

 

 

 

 

PAH/PPH Home | PAH/PPH Causes | PAH/PPH Symptoms | PAH/PPH Pictures | Treatment Options | Medications | PAH/PPH Doctor Locator | PAH/PPH Clinic Locator | PAH/PPH Questions | PAH/PPH Support | Patient Handouts | Financial Aid | PAH/PPH News | Site Map